Literature DB >> 9358504

Prediction of arrhythmia risk based on signal-averaged ECG in postinfarction patients.

M Borggrefe1, T Fetsch, A Martínez-Rubio, M Mäkijärvi, G Breithardt.   

Abstract

In patients surviving acute MI, identification of those at high risk for life-threatening ventricular tachyarrhythmias and/or sudden death is of great importance. Numerous strategies based on indices such as the degree of left ventricular dysfunction, complex ventricular arrhythmias, or parameters of autonomic dysfunction have not yet led to an effective identification of the individual patient at risk. During the past decade, many investigators have recorded low amplitude, high frequency components in the terminal QRS complex (so-called late potentials) from patients prone to sustained ventricular tachycardia. The SAECG has been used to predict life-threatening tachyarrhythmias in patients after acute MI and to screen for inducible ventricular tachycardia in patients with unexplained syncope or sustained ventricular tachycardia. This review article describes the most frequently applied methodology and clinical applications of the SAECG in post-MI patients and discusses the usefulness of noninvasive recordings in various other clinical settings.

Entities:  

Mesh:

Year:  1997        PMID: 9358504     DOI: 10.1111/j.1540-8159.1997.tb06106.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  2 in total

1.  Late potential analysis: is a mathematically-derived X,Y,Z lead system comparable to a true orthogonal X,Y,Z lead system?

Authors:  Thomas A Cron; Michael J Zellweger; Peter T Buser; Matthias E Pfisterer; Stefan Osswald
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-10       Impact factor: 1.468

2.  The Impact of Hospital-Based Cardiac Rehabilitation on Signal Average ECG Parameters of the Heart After Myocardial Infarction.

Authors:  Mohammadvahid Jorat; Sina Raafat; Zahra Ansari; Leila Mahdavi-Anari; Mahdieh Ghanbari-Firoozabadi
Journal:  Res Cardiovasc Med       Date:  2015-08-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.